Synthetic Biologics (SYN) Stock Rating Upgraded by Zacks Investment Research

Synthetic Biologics (NYSEAMERICAN:SYN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, reports.

According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “

Shares of Synthetic Biologics stock opened at $0.62 on Thursday. Synthetic Biologics has a 1 year low of $0.51 and a 1 year high of $10.43.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings data on Wednesday, February 27th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.95).

In other news, major shareholder Randal J. Kirk sold 150,565 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $0.66, for a total value of $99,372.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

A hedge fund recently raised its stake in Synthetic Biologics stock. Virtu Financial LLC increased its position in Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 669.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,070 shares of the company’s stock after purchasing an additional 81,852 shares during the quarter. Virtu Financial LLC owned approximately 0.61% of Synthetic Biologics worth $64,000 at the end of the most recent quarter.

About Synthetic Biologics

Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.

See Also: Call Option Volume

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.